logo
Plus   Neg
Share
Email

J. C. Penney Q3 Loss Narrows, Reaffirms FY19 Comp Sales Outlook - Quick Facts

J. C. Penney Co., Inc. (JCP) reported Friday a third-quarter net loss of $93 million, or $0.29 per share, narrower than a net loss of $151 million, or $0.48 per share in the prior-year quarter.

Excluding items, adjusted net loss for the quarter was $97 million, or $0.30 per share, compared to an adjusted net loss of $164 million, or $0.52 per share in the year-ago quarter.

Total net sales for the quarter decreased 10.1 percent to $2.38 billion from last year's $2.65 billion. Comparable sales decreased 9.3 percent and adjusted comparable store sales, which exclude the impact of the company's exit from major appliance and in-store furniture categories, decreased 6.6 percent for the quarter.

On average, analysts polled by Thomson Reuters expected the company to report a loss of $0.55 per share on sales of $2.51 billion for the quarter. Analysts' estimates typically exclude special items.

Looking ahead to fiscal 2019, the company continues to expect comparable store sales to decline in a range of 7.0 to 8.0 percent and adjusted comparable store sales to decline in a range of 5.0 to 6.0 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry. Graco Inc. (GGG) shares were climbing more than 7 percent in morning trade. Monday after market close, the company had reported a surge in the fourth-quarter earnings to $84.8 million from $73.7 million in the prior year. Earnings per share surpassed analysts' estimates. Sales were up 1 percent to $412.3... Strategy of getting multiple indication approvals for the same drug seems to be paying off for AstraZeneca PLC (AZN), in terms of higher likelihood of approval and improved sales. Besides, the company is realizing value from non-core, mature brands to invest in new drugs, which also seems to be working in its favor.
Follow RTT
>